

Functional Serum Response Elements Upstream of the Growth Factor-Inducible Gene *zif268*

BARBARA CHRISTY AND DANIEL NATHANS*

*Howard Hughes Medical Institute and Department of Molecular Biology and Genetics,
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205*

Received 22 June 1989/Accepted 15 August 1989

The *zif268* gene, which encodes a protein with three typical zinc finger sequences, is induced in mouse 3T3 cells by serum, phorbol 12-myristate 13-acetate platelet-derived growth factor, and fibroblast growth factor. The induction is coordinate with that of *c-fos*. The 5'-flanking region of *zif268* contains sequences that resemble known regulatory elements, including four CC(A or T)₆GG sequences similar to the core serum response elements (SREs) found upstream of *c-fos* and actin genes. To determine whether the *zif268* SRE-like elements mediate induction, CAT (chloramphenicol acetyltransferase) plasmids with different lengths of *zif268* upstream sequences were tested for inducibility in 3T3 cells by serum, platelet-derived growth factor, or phorbol 12-myristate 13-acetate. In addition, double-stranded oligonucleotides corresponding to each of the four *zif268* putative SREs were tested individually for responsiveness when placed upstream of a thymidine kinase gene promoter. Each of the four SREs conferred inducibility by the agents tested, and multiple SREs resulted in greater inducibility than did a single element. Each of the *zif268* SREs also competed with the *c-fos* SRE for binding by serum response factor present in HeLa cell nuclear extract. We conclude that the *zif268* SRE-like sequences are functional and probably account for the coordinate induction of *zif268* and *c-fos*.

Growth factors and other extracellular ligands rapidly induce the expression of genes that appear to mediate the cellular response to the ligand. Some of these immediate-early or early-response genes encode known or probable regulators of transcription. Among the induced genes of this type in murine 3T3 cells are *fos* (15), *c-jun* (20, 43), *junB* (42), *Krox-20* (6), *nur77* (*NGFI-B*), (17, 30), *zif268* (7) (also designated *NGFI-A* [29], *egr-1* [46], and *Krox-24* [24]), *fra-1* (8), and *fosB* (51). Many of these genes are coordinately activated by serum or platelet-derived growth factor (PDGF) in mouse 3T3 cells (21, 22) and by epidermal growth factor or nerve growth factor in rat PC12 cells (2). Several also appear to be coordinately activated in hippocampal neurons of the rat during pharmacologically induced seizures (44).

The activation of *fos* by serum, PDGF, or epidermal growth factor has been shown to be mediated at least in part by an upstream *cis* element called the serum response element (SRE) (10-12, 14, 39, 47, 48). This 22-base-pair DNA sequence has dyad symmetry and is the binding site for a 67-kilodalton protein called the serum response factor (SRF) (40, 49). We and others (4, 7, 50) have found that the 5' DNA sequence preceding the transcription start site of *zif268* contains a number of potential binding sites for known transcription factors, including core Sp1 sites, an AP-2-like site, an AP-1-like site, two CCAAT sequences, a probable cyclic AMP response element, and four sequences that resemble the core sequence of the *fos* and actin SREs (4, 7, 50). All four of the *zif268* SRE-like sequences contain a core of 10 nucleotides (CC[A or T]₆GG) present in the *fos* and actin SREs (34), but they differ in flanking sequence from the *fos* and actin signals and from each other. In view of the possibility that the coordinate induction of *fos* and *zif268* by serum or growth factors is mediated by SRF binding to SREs, we determined whether the *zif268* SRE-like sequences actually function as SREs and whether they bind SRF.

MATERIALS AND METHODS

Construction of *zif*-CAT fusions and deletions. A bacteriophage containing the *zif268* mRNA sequences and genomic flanking sequences on both the 5' and 3' sides was isolated from a BALB/c embryonic DNA library (obtained from P. Leder) by using a cDNA probe. A *Bgl*II fragment of approximately 2.8 kilobase pairs (kb) containing the 5' end of the cDNA and approximately 2.5 kb of 5'-flanking sequence was subcloned upstream of the chloramphenicol acetyltransferase (CAT)-coding sequence in plasmid pBLUECAT-2 (constructed by L. Sanders). The construct contains the 5' end of the long open reading frame of the *zif268* mRNA fused in frame with the CAT gene open reading frame. (However, it is not known whether this part of the open reading frame is actually translated in vivo or whether another AUG, not present in this fragment, is used.) This construct was previously shown to be inducible by serum in transient assays (7). 5' deletions were made by using exonuclease III and S1 nuclease as previously described (7). The deletion endpoints were determined by dideoxynucleotide sequencing. The 5' endpoint of the -2500 construct was estimated from the electrophoretic mobility of the cloned fragment. For analysis of individual SRE-like elements, oligonucleotides corresponding to both strands of each putative SRE and to the *c-fos* SRE were synthesized with *Bam*HI and *Bgl*II ends. Each pair of oligonucleotides was annealed and cloned into the *Bam*HI site of plasmid pBLCAT-2, which contains the thymidine kinase (TK) gene promoter upstream of the CAT-coding sequences (28). The sequences of the insertion sites were determined, and for purposes of comparison, clones were selected that contained a single copy of each oligonucleotide in the naturally occurring orientation.

Cell culture and transfections. NIH 3T3 cells were cotransfected with the *zif*-CAT plasmid and pCH110, a plasmid containing the β -galactosidase-coding sequences under the control of the simian virus 40 early promoter (16), as previously described (7). After transfection, cells were starved for 2 days in the presence of 0.5% fetal bovine serum

* Corresponding author.




FIG. 1. (A) Physical map of the upstream region of *zif268* and sequences of SRE-like elements. Symbols: □, sequences 5' to the start of transcription; ▨, sequences corresponding to transcribed sequences; ---, region between -600 and approximately -2500, which is not shown on this map. Numbers below the line indicate locations of 5' endpoints of CAT deletion constructs. Sequences related to known regulatory elements are indicated by boxes and symbols above the line: T, TATA box; C, cyclic AMP response element-like element; S, Sp1 core sequences; A, AP-1-like site. Numbers 1 to 4 indicate the positions of four SRE-like elements located in the *zif268* promoter, with the most proximal element designated as 1. (B) Sequences of the SRE-like elements in comparison with the *fos* SRE sequence.

(FBS). At appropriate times before harvest, cells were stimulated by addition of 20% FBS, 10 ng of PDGF (BB homodimer; Genzyme Corp.) per ml, or 2 ng of phorbol 12-myristate 13-acetate (PMA; Sigma Chemical Co.) per ml. After harvest, the CAT and β -galactosidase activities were determined (13, 31). In Results, CAT activity is expressed as percent conversion per unit of β -galactosidase to correct for differences in the efficiency of transfection and protein content in the various extracts.

DNA-binding assay. Double-stranded oligonucleotides corresponding to the *c-fos* SRE were labeled with [32 P]dATP and [32 P]dCTP, using the Klenow fragment of DNA polymerase I, as described previously (36). HeLa nuclear extract, prepared by the method of Dignam et al. (9), was generously provided by E. Perez-Albuerna. Binding was carried out in 25 μ l of 10 mM Tris (pH 7.5)–50 mM NaCl–1 mM dithiothreitol–1 mM EDTA–5% glycerol containing 50 μ g of sonicated salmon sperm DNA per ml. HeLa cell nuclear extract (9.7 μ g per reaction) was incubated without 32 P-labeled DNA at room temperature for 10 min; 32 P-labeled fragment was added to a final probe concentration of 0.5 nM, and the reaction mixtures were incubated 20 min longer at room temperature. Competitors used were double-stranded oligonucleotides corresponding to the various SREs and were included in the preincubation step (before addition of labeled fragment). After incubation, 5 μ l of 0.1% bromophenol blue–0.1% xylene cyanol was added, and the entire reaction mixture was loaded onto a 6% polyacrylamide gel (30 parts of acrylamide/0.8 parts of bisacrylamide) and run in 0.25 \times TBE (TBE is 89 mM boric acid, 89 mM Tris base, and 2 mM EDTA). Electrophoresis was carried out at 175 V at room temperature, with recirculation of the buffer.

RESULTS

Effect of progressive deletion of *zif268* SRE-like elements on gene activation. In the first series of experiments to be described, a recombinant *zif*-CAT fusion gene was used for analyzing the effect of deleting SRE-like sequences on serum or growth factor induction of the downstream CAT gene. To construct the test plasmid, a genomic *zif268* clone containing the entire gene and 5'- and 3'-flanking sequences was first

isolated from a BALB/c mouse embryo library. A 2.8-kb *Bgl*II fragment derived from this clone and containing approximately 2.5 kb of sequence upstream of the transcription start site and 339 base pairs corresponding to the 5' end of the mRNA was ligated into the *Bgl*II site of the vector pBLCAT-3 (28) such that the coding sequence of *zif268* was fused in frame to the first codon of the CAT gene. We have shown previously that when a plasmid containing this construct was used to transfect NIH 3T3 cells, CAT activity was induced by serum (7). 5' deletions of the *zif*-CAT recombinant were made by using exonuclease III, and the endpoint of each deletion was determined by DNA sequencing (Fig. 1). Each construct was transfected into NIH 3T3 cells and tested for inducibility of CAT activity by 20% fetal bovine serum, PMA, or PDGF as described in Materials and Methods.

Both the full-length plasmid and the -594 plasmid, which have all four SRE-like elements (Fig. 1), showed marked stimulation of CAT expression by serum, PMA, and PDGF (Fig. 2). The -166 and -119 constructs, which had lost the two distal SRE-like sequences (Fig. 1), retained responsiveness to serum, PMA, and PDGF, but both the basal level and the stimulated level of CAT were considerably lower than was seen with the full-length plasmid or the -594 construct. The -91 construct, with one remaining SRE-like sequence (Fig. 1), showed a very low basal of CAT expression and slight or no response to the three stimulants, whereas the -61 construct, with no SRE-like sequences, had no detectable basal or stimulated expression. In sum, in the construct containing the most proximal element (SRE 1) alone, there was little activity, the construct with SREs 1 and 2 was more active, and the construct with SREs 1 to 4 was most active. Since sequences other than SREs had been deleted and the basal level of CAT expression was affected by deletion, it is not clear from these results whether SRE 1 is active or what the relative activity of each SRE is. However, the results suggest that all four SREs together are more active than the two proximal SREs.

Activity of individual SRE-like elements. To determine whether the single *zif268* SREs are functional, oligonucleotides corresponding to each *zif268* SRE and to the *c-fos* SRE




FIG. 2. Induction of CAT activity in cells transfected with *zif*-CAT plasmids after treatment with 20% FBS, 2 ng of PMA per ml, or 10 ng of PDGF per ml. NIH 3T3 cells were cotransfected with *zif*-CAT plasmids and the β -galactosidase plasmid pCH110 and were then serum-starved and stimulated as described in the text. (A) Typical autoradiogram of chloramphenicol acetylation products after incubation of extracts of serum-stimulated cells with [14 C]chloramphenicol. The times after serum addition are given below the panels; numbers to the left indicate the amount of 5'-flanking sequence retained in each construct (Fig. 1). Similar autoradiograms were obtained after PMA and PDGF induction. (B) Graphs indicating CAT activity for each construct at 0, 2, and 4 h after induction, normalized to the β -galactosidase activity in equivalent amounts of each cell extract. Bars indicate the standard error of the mean for duplicate dishes. (Where the variation was too small, bars were omitted). In each panel, two separate experiments have been combined. In the case of FBS and PMA, experiment 1 included constructs -2500 to -63.

were synthesized with *Bam*HI and *Bgl*II ends and ligated into the *Bam*HI site of the vector pBLCAT-2 (28) upstream of the TK gene promoter of the vector (-105 to +51), which controls the CAT gene. Cells were then transfected with

each construct, and induction of CAT by serum, PDGF, or PMA was determined (Fig. 3). (Less extensive experiments with fibroblast growth factor gave similar results [data not shown].) All oligonucleotides were active, and SRE 3 ap-





FIG. 3. Responsiveness of individual *zif268* SRE elements when cloned upstream of the herpes simplex virus TK gene promoter. (A) Typical autoradiogram of chloramphenicol acetylation products after incubation of cell extracts with [14 C]chloramphenicol. Time after stimulation with 20% FBS is shown below each panel. The constructs 268-OL1, -OL2, -OL3, and -OL4 each contain one copy of the *zif268* SRE-like sequences 1 to 4 (see Fig. 1 for sequences) in the orientation naturally found in the *zif268* promoter. The FOS-OL construct contains one copy of the *c-fos* SRE inserted upstream of the TK-CAT sequences as a positive control. pBLCAT-2 refers to the TK-CAT vector alone, without inserted oligonucleotide sequences. (B) Graphs indicating CAT activity for each construct at 0, 2, and 4 h after induction, normalized to β -galactosidase activity in equivalent amounts of each extract. Bars indicate the standard error of the mean for duplicate dishes. (Where the variation was too small, bars were omitted.)



peared to be more responsive to serum than were the other *zif268* SREs. The response of each *zif268* element was similar to that of the *fos* SRE (Fig. 3). We conclude that each element, including SRE 1, can function as an SRE. When two copies of an SRE oligonucleotide were inserted 5' to the TK gene promoter, inducibility by serum was greater than with a single copy (Fig. 4), again indicating that multiple copies of an SRE enhance the effect, as shown for the *fos* SRE (48). Also shown in Fig. 4 is the importance of the spacing between the C · G pairs in the core SRE sequence. When one A · T pair was deleted in the OL2 core sequence, giving the sequence (GTCCTTCCATATAGGGCTTCC), the oligonucleotide did not confer serum responsiveness. In contrast, deletion of a base pair in the sequence flanking the core had no effect (Fig. 4).

Binding of *zif268* SREs by SRF. The *fos* and *zif268* SREs share the core CC(A or T)₆GG sequence, but the *zif268* SREs lack the flanking symmetrical sequences present in the *fos* SRE (47). To determine whether the various SREs are bound by the same protein, we used a nuclear extract from HeLa cells as a source of SRF (48) and determined whether each of the *zif268* SREs inhibits the binding of *fos* SRE by

SRF. Each of the *zif268* SRE oligonucleotides competed with the *fos* SRE for binding by the nuclear extract, although SRE 2 was less active than the others (FIG. 5a). (Note that the SRE 2 core sequence is identical to that of the *fos* SRE.) We conclude that all four *zif268* SREs are binding sites for the SRF, but either the precise AT sequence of the core or the flanking sequences affect the efficiency of binding. When a modified SRE sequence containing five A · T pairs as spacer was tested, it competed very poorly with the *fos* SRE for binding by HeLa cell SRE (Fig. 5b). A naturally occurring SRE-related sequence containing five A · T base pairs from the *zif268* promoter (nucleotides -341 to -320) was also tested in this assay (core sequences




FIG. 4. Serum responsiveness of plasmids containing mutations in the OL2 SRE sequences. NIH 3T3 cells were cotransfected with pCH110 and with the OL2 oligonucleotide (which contains the wild-type *zif268* SRE2 sequences 5' of the TK-CAT sequences in pBLCAT-2) or with plasmids carrying mutations in the SRE sequences. After serum deprivation and stimulation by 20% FBS, the amount of CAT activity of cell extracts was determined and normalized to the amount of β -galactosidase activity. Columns: 1, OL2 wild-type plasmid; 2, a derivative of OL2 that contains a deletion of one nucleotide in the flanking sequences of the SRE (GTCCTTC CATATTAGGGCTTCC); 3, a derivative of OL2 that contains a deletion in the core A and T residues (GTCCTTCCATATAGGGCT TCC); 4 and 5, two separate constructs containing two tandem copies of the OL2 SRE sequences; 6, pBLCAT-2 vector alone.

..CCAATATGG..) and failed to compete with the *fos* SRE for binding (data not shown).

DISCUSSION

In 3T3 cells, the *zif268* promoter appears to be activated by serum, PDGF, and PMA, at least in part, via its four SREs. Deletion of upstream sequences that include all four SREs abolished induction of a downstream gene, and the presence of multiple SREs led to greater induction than did the presence of a single SRE. Our deletion experiments, however, do not exclude a role for other upstream sequences in induction by serum or the other inducers tested. When assayed separately in a TK-CAT construct, each *zif268* SRE was about as active as the *fos* SRE. This result correlated with the ability of the *zif268* SREs to compete with the *fos* SRE for binding to SRF present in a nuclear extract of HeLa cells, although the poorer competition by SRE2 was not reflected in the expression assay. Taken together, the results strongly support the hypothesis that in 3T3 cells the coordinate activation of *fos* and *zif268* by the ligands tested is mediated, at least in part, by the binding of SRF to the respective SREs.

Previous studies of serum inducibility of *Krox-20*, another immediate-early gene related to *zif268*, also implicate SREs in the coordinate responsiveness of immediate-early genes (5). Why *zif268* has four functional SREs, *Krox-20* has two, and *fos* has only one is not clear. One would expect that at a limiting concentration of SRF, *zif268* would be induced to a greater extent than *fos*. In 3T3 cells, *zif268* appears to be




FIG. 5. (A) Competition between *zif268* SREs and the *c-fos* SRE for HeLa cell SRF. Binding reactions were carried out as described in the text, using 9.7 μ g of HeLa nuclear extract protein and 0.5 nM 32 P-labeled *c-fos* SRE oligonucleotide per reaction. Oligonucleotide competitor DNAs were incubated with the extracts before addition of labeled DNA. The arrowheads point to the specific complexes formed upon incubation with the *c-fos* SRE. Lanes: 1, probe alone (no extract); 2, 15, and 24, no competitor; 3 to 6, competition with the *c-fos* double-stranded oligonucleotide itself; 7 to 10, competition with OL1; 11 to 14, competition with OL2; 16 to 19, competition with OL3; 20 to 23, competition with OL4. Competitor DNA was used in 2-fold (lanes 3, 7, 11, 16, and 20), 5-fold (lanes 4, 8, 12, 17, and 21), 10-fold (lanes 5, 9, 13, 18, and 22), and 25-fold (lanes 6, 10, 14, 19, and 23) molar excesses of competitor DNA over probe DNA. (B) Effect of deletion of one of the core AT nucleotides on the ability of the OL1 oligonucleotide to compete with the *c-fos* SRE element for SRF binding. Binding reactions were carried out as described above. The arrowhead points to the complexed *c-fos* SRE. Lanes: 1, probe alone (no extract); 2, no competitor; 3 to 6, competition with the OL1 wild-type oligonucleotide; 7 to 10, competition with the OL1 mutant oligonucleotide (core sequence CCAATATAGG). Competitor DNA was used in 2-fold (lanes 3 and 7), 5-fold (lanes 4 and 8), 10-fold (lanes 5 and 9), and 50-fold (lanes 6 and 10) molar excesses of DNA over probe DNA.

induced slightly earlier than *fos*, but there is little difference in the degree of induction (22). Possibly, other factors influence induction of each gene by serum growth factors. In this regard, there is evidence that a protein that binds to a sequence adjacent to the core SRE of *fos* is involved in serum responsiveness (45). This putative protein-binding site is not present in the sequence flanking the core SRE of any of the *zif268* elements. Thus, the *fos* response, but not that of *zif268*, may be enhanced by binding of a second protein adjacent to the SRE.

Whereas the SREs of *fos* have extensive dyad symmetry outside the core sequence, the SREs of *zif268* do not. Both methylation protection and interference experiments (34) and mutational analysis (11, 14, 25) indicated that the C · G base pairs of the *fos* core SRE are important for activity, and the *zif268* mutant SRE missing one core A · T pair confirms that spacing of the CC-GG contact sites is important. Other functional SREs, notably four such elements upstream of the human α -cardiac actin gene (32) and two upstream or in the first intron of *Krox-20* (5), also do not show the dyad symmetry external to the core CC(A or T)₆GG of the *fos* SRE. In the case of the α -cardiac actin SREs, one of the core sequences contains a G · C pair in the A+T-rich sequence; hence, the α -cardiac actin elements have been called the CArG box (for CC[A + T rich]₆GG) (32, 38). Like the four *zif268* SREs, both the CArG boxes upstream of the α -cardiac actin gene and the SREs found in *Krox-20* also compete with the *fos* SRE for binding to SRF prepared from HeLa cell nuclei (3, 5). Therefore, the SRF can bind to DNA sequences that retain the CC(A or T rich)₆GG core sequence. However, the relative affinity of SRF for different sites is influenced by flanking sequences (25, 37; Fig. 5).

As indicated earlier, the sequence upstream of *zif268* contains potential binding sites for other regulatory proteins: Sp1 (19), CREB or ATF (27, 35), AP-1 (1, 23), and AP-2 (18, 33). Since the *zif268* gene is transiently induced in many cell types and by different ligands, some of these binding sites may mediate activation of *zif268* in specific cells or by specific ligands, and others may be involved in the rapid shutoff of the gene seen after cell stimulation. Recent reports of a second protein that binds to the *fos* SRE (26, 41) raise the additional possibility that different SRF-like proteins may mediate the responses of *fos* and *zif268* in different types of cells.

ACKNOWLEDGMENTS

We thank Laura Sanders for technical assistance and advice on performing CAT assays, Brien Byers and Clark Riley for oligonucleotides, Evelio Perez-Albuera for HeLa nuclear extract, Yusaku Nakabeppu for advice on DNA-binding assays, and Lily Mitchell for preparation of the manuscript.

This research was supported in part by Public Health Service grant 5 PO1 CA16519 from the National Cancer Institute.

LITERATURE CITED

- Angel, P., M. Imagawa, R. Chiu, B. Stein, R. J. Imbra, H. J. Rahmsdorf, C. Jonat, P. Herrlich, and M. Karin. 1987. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. *Cell* **49**:729-739.
- Bartel, D. P., M. Sheng, L. F. Lau, and M. E. Greenberg. 1989. Growth factors and membrane depolarization activate distinct programs of early response gene expression: dissociation of *fos* and *jun* induction. *Genes Dev.* **3**:304-313.
- Boxer, L. M., R. Prywes, R. G. Roeder, and L. Kedes. 1989. The sarcomeric actin CArG-binding factor is indistinguishable from the *c-fos* serum response factor. *Mol. Cell. Biol.* **9**:515-522.
- Changelian, P. S., P. Feng, T. C. King, and J. Milbrandt. 1989. Structure of the NGFI-A gene and detection of upstream sequences responsible for its transcriptional induction by nerve growth factor. *Proc. Natl. Acad. Sci. USA* **86**:377-381.
- Chavrier, P., U. Janssen-Timmen, M.-G. Mattéi, M. Zerial, R. Bravo, and P. Charnay. 1989. Structure, chromosomal location, and expression of the mouse zinc finger gene *Krox-20*: multiple gene products and coregulation with the proto-oncogene *c-fos*. *Mol. Cell. Biol.* **9**:787-797.
- Chavrier, P., M. Zerial, P. Lemaire, J. Almendral, R. Bravo, and P. Charnay. 1988. A gene encoding a protein with zinc fingers is activated during G0/G1 transition in cultured cells. *EMBO J.* **7**:29-35.
- Christy, B. A., L. F. Lau, and D. Nathans. 1988. A gene activated in mouse 3T3 cells by serum growth factors encodes a protein with "zinc finger" sequences. *Proc. Natl. Acad. Sci. USA* **85**:7857-7861.
- Cohen, D. R., and T. Curran. 1988. *fra-1*: a serum-inducible, cellular immediate-early gene that encodes a Fos-related antigen. *Mol. Cell. Biol.* **8**:2063-2069.
- Dignam, J. D., R. M. Lebovitz, and R. G. Roeder. 1983. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. *Nucleic Acids Res.* **11**:1475-1489.
- Fisch, T. M., R. Prywes, and R. G. Roeder. 1987. *c-fos* sequences necessary for basal expression and induction by epidermal growth factor, 12-*O*-tetradecanoyl phorbol-13-acetate, and the calcium ionophore. *Mol. Cell. Biol.* **7**:3490-3502.
- Gilman, M. Z. 1988. The *c-fos* serum response element responds to protein kinase C-dependent and -independent signals but not to cyclic AMP. *Genes Dev.* **2**:394-402.
- Gilman, M. Z., R. N. Wilson, and R. A. Weinberg. 1986. Multiple protein-binding sites in the 5'-flanking region regulate *c-fos* expression. *Mol. Cell. Biol.* **6**:4305-4316.
- Gorman, C. M., L. F. Moffat, and B. H. Howard. 1982. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. *Mol. Cell. Biol.* **2**:1044-1051.
- Greenberg, M. E., Z. Siegfried, and E. B. Ziff. 1987. Mutation of the *c-fos* gene dyad symmetry element inhibits serum inducibility of transcription in vivo and the nuclear regulatory factor binding in vitro. *Mol. Cell. Biol.* **7**:1217-1225.
- Greenberg, M. E., and E. B. Ziff. 1984. Stimulation of 3T3 cells induces transcription of the *c-fos* proto-oncogene. *Nature (London)* **311**:433-437.
- Hall, C., E. Jacob, G. Ringold, and F. Lee. 1983. Expression and regulation of *Escherichia coli lac Z* gene fusions in mammalian cells. *J. Mol. Appl. Genet.* **2**:101-109.
- Hazel, T. G., D. Nathans, and L. F. Lau. 1988. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily. *Proc. Natl. Acad. Sci. USA* **85**:8444-8448.
- Imagawa, M., R. Chiu, and M. Karin. 1987. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. *Cell* **51**:251-260.
- Kadonaga, J. T., K. A. Jones, and R. Tjian. 1986. Promoter-specific activation of RNA-polymerase II transcription by Sp1. *Trends Biochem. Sci.* **12**:464-469.
- Lamph, W. W., P. Wamsley, P. Sassone-Corsi, and I. M. Verma. 1988. Induction of proto-oncogene JUN/AP-1 by serum and TPA. *Nature (London)* **334**:629-631.
- Lau, L. F., and D. Nathans. 1985. Identification of a set of genes expressed during the G0/G1 transition of cultured mouse cells. *EMBO J.* **4**:3145-3151.
- Lau, L. F., and D. Nathans. 1987. Expression of a set of growth-related immediate early genes in BALB/c 3T3 cells: coordinate regulation with *c-fos* or *c-myc*. *Proc. Natl. Acad. Sci. USA* **84**:1182-1186.
- Lee, W., P. Mitchel, and R. Tjian. 1987. Purified transcription factor AP-1 interacts with TPA-inducible enhancer elements. *Cell* **49**:741-752.
- Lemaire, P., O. Revelent, R. Bravo, and P. Charnay. 1988. Two mouse genes encoding potential transcription factors with identical DNA-binding domains are activated by growth factors in cultured cells. *Proc. Natl. Acad. Sci. USA* **85**:4691-4695.

25. Leung, S., and N. G. Miyamoto. 1989. Point mutational analysis of the human *c-fos* serum response factor binding site. *Nucleic Acids Res.* 17:1177-1194.
26. Levi, B.-Z., J. W. Kasik, P. A. Burke, R. Prywes, R. G. Roeder, E. Appella, and K. Ozato. 1989. Neonatal induction of a nuclear protein that binds to the *c-fos* enhancer. *Proc. Natl. Acad. Sci. USA* 86:2262-2266.
27. Lin, Y.-S., and M. R. Green. 1988. Interaction of a common cellular transcription factor, ATF, with regulatory elements in both *Ela*- and cyclic AMP-inducible promoters. *Proc. Natl. Acad. Sci. USA* 85:3396-3400.
28. Luckow, B., and G. Schütz. 1987. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. *Nucleic Acids Res.* 15:5490.
29. Milbrandt, J. 1987. A nerve growth factor-induced gene encodes a possible transcriptional regulatory factor. *Science* 238:797-799.
30. Milbrandt, J. 1988. Nerve growth factor induces a gene homologous to the glucocorticoid receptor gene. *Neuron* 1:183-188.
31. Miller, J. H. 1972. Experiments in molecular genetics, p. 352-355. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
32. Minty, A., and L. Kedes. 1986. Upstream regions of the human cardiac actin gene that modulate its transcription in muscle cells: presence of an evolutionary conserved repeated motif. *Mol. Cell. Biol.* 6:2125-2136.
33. Mitchell, P. J., C. Wang, and R. Tjian. 1987. Positive and negative regulation of transcription in vitro: enhancer-binding protein AP-2 is inhibited by SV40 T antigen. *Cell* 50:847-861.
34. Mohun, T., N. Garrett, and R. Treisman. 1987. *Xenopus* cytoskeletal actin and human *c-fos* gene promoters share a conserved protein-binding site. *EMBO J.* 6:667-673.
35. Montminy, M. R., K. A. Sevarino, J. A. Wagner, G. Mandel, and R. Goodman. 1986. Identification of a cyclic-AMP-responsive element within the rat somatostatin gene. *Proc. Natl. Acad. Sci. USA* 83:6682-6686.
36. Nakabeppu, Y., K. Ryder, and D. Nathans. 1988. DNA binding activities of three murine *jun* proteins: stimulation by Fos. *Cell* 55:907-915.
37. Norman, C., and R. Treisman. 1988. Analysis of serum response element function in vitro. Cold Spring Harbor Symp. Quant. Biol. 53:719-726.
38. Phan-Dinh-Tuy, F., D. Tuil, F. Schweighoffer, C. Pinset, A. Kahn, and A. Minty. 1988. The 'CC.Ar.GG' box. A protein-binding site common to transcription-regulatory regions of the cardiac actin, *c-fos* and interleukin-2 receptor genes. *Eur. J. Biochem.* 173:507-515.
39. Prywes, R., and R. G. Roeder. 1986. Inducible binding of a factor to the *c-fos* enhancer. *Cell* 47:777-784.
40. Prywes, R., and R. G. Roeder. 1987. Purification of the *c-fos* enhancer-binding protein. *Mol. Cell. Biol.* 7:3482-3489.
41. Ryan, W. A., Jr., B. R. Franza, Jr., and M. Z. Gilman. 1989. Two distinct cellular phosphoproteins bind to the *c-fos* serum response element. *EMBO J.* 8:1785-1792.
42. Ryder, K., L. F. Lau, and D. Nathans. 1988. A gene activated by growth factors is related to the oncogene *v-jun*. *Proc. Natl. Acad. Sci. USA* 85:1487-1491.
43. Ryder, K., and D. Nathans. 1988. Induction of protooncogene *c-jun* by serum growth factors. *Proc. Natl. Acad. Sci. USA* 85:8464-8467.
44. Saffen, D. W., A. J. Cole, P. F. Worley, B. A. Christy, K. Ryder, and J. M. Baraban. 1988. Convulsant-induced increase in transcription factor messenger RNAs in rat brain. *Proc. Natl. Acad. Sci. USA* 85:7795-7799.
45. Shaw, P. E., H. Schroter, and A. Nordheim. 1989. The ability of a ternary complex to form over the serum response element correlates with serum inducibility of the human *c-fos* promoter. *Cell* 56:563-572.
46. Sukhatme, V. P., X. Cao, L. C. Chang, C.-H. Tsai-Morris, D. Stamenkovich, P. C. P. Ferreira, D. R. Cohen, S. A. Edwards, T. B. Shows, T. Curran, M. M. LeBeau, and E. D. Adamson. 1988. A zinc finger-encoding gene coregulated with *c-fos* during growth and differentiation, and after cellular depolarization. *Cell* 53:37-43.
47. Treisman, R. 1985. Transient accumulation of *c-fos* RNA following serum stimulation requires a conserved 5' element and *c-fos* sequences. *Cell* 42:889-902.
48. Treisman, R. 1986. Identification of a protein-binding site that mediates transcriptional response of the *c-fos* gene to serum factors. *Cell* 46:567-574.
49. Treisman, R. 1987. Identification and purification of a polypeptide that binds to the *c-fos* serum response element. *EMBO J.* 6:2711-2717.
50. Tsai-Morris, C.-H., X. Cao, and V. P. Sukhatme. 1988. 5' flanking sequence and genomic structure of *Egr-1*, a murine mitogen inducible zinc finger encoding gene. *Nucleic Acids Res.* 16:8835-8846.
51. Zerial, M., L. Toschi, R.-P. Ryseck, M. Schuermann, R. Müller, and R. Bravo. 1989. The product of a novel growth factor activated gene, *fos B*, interacts with JUN proteins enhancing their DNA binding activity. *EMBO J.* 8:805-813.